NCT04146623 - Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

October 11, 2020

Study Completion Date

November 11, 2020

Conditions

Influenza

Interventions

BIOLOGICAL

CodaVax-H1N1 influenza vaccine

CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10\^5 plaque forming units (PFU).

BIOLOGICAL

Normal Saline Placebo

Saline (0.9%) administered intranasally via sprayer

Trial Locations (1)

4006

Q-Pharm Pty Limited, Brisbane